Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | TPH1 | P17752 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513654 | 0.88 | NPC1 (0.41) | KMT2ANPC1RAB9AS1PR1ALDH1A1 | |
| SCHEMBL17513132 | 0.80 | GAA (0.35) | KMT2ANPC1RAB9AS1PR1ALDH1A1 | |
| SCHEMBL17513652 | 0.79 | SCN9A (0.35) | NPC1RAB9AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL17513116 | 0.77 | KMT2A (0.39) | KMT2ANPC1RAB9AS1PR1ALDH1A1 | |
| SCHEMBL17513666 | 0.76 | CNR1 (0.44) | KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL16741034 | 0.72 | TPH1 (0.47) | NPC1RAB9AALDH1A1TPH1 | |
| SCHEMBL19915961 | 0.72 | S1PR4 (0.61) | KMT2AS1PR4GRM5HCRTR1ALDH1A1 | |
| SCHEMBL2490015 | 0.71 | KMT2A (0.45) | KMT2AS1PR1S1PR4GRM5ALDH1A1 | |
| SCHEMBL2486981 | 0.71 | KMT2A (0.45) | KMT2AS1PR1S1PR4GRM5ALDH1A1 | |
| SCHEMBL26140304 | 0.70 | S1PR4 (0.41) | KMT2AS1PR4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182962-B1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10905683-B2 | Compositions and uses of amidine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| EP-3182962-A1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | Biocryst Pharmaceuticals, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029214-A9 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016029214-A1 | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905683-B2 | Compositions and uses of amidine derivatives | HRH3, HRH2, HRH1 | KMT2A 3712/4885NPC1 1391/4885RAB9A 1111/4885 |
| US-20170266172-A1 | Compositions and Uses of Amidine Derivatives | HRH3, HRH2, HRH1 | KMT2A 3712/4885NPC1 1391/4885RAB9A 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.